Organon & Co. (OGN) is a publicly traded Healthcare sector company. As of May 21, 2026, OGN trades at $13.40 with a market cap of $3.52B and a P/E ratio of 14.29. OGN moved +0.34% today. Year to date, OGN is +80.91%; over the trailing twelve months it is +53.65%. Its 52-week range spans $5.69 to $19.41. Analyst consensus is neutral with an average price target of $11.25. Rallies surfaces OGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Legal Challenge Targets Organon $14-Per-Share Sale to Sun Pharma: Organon & Co.’s $14 per share sale to Sun Pharma faces legal scrutiny over potential insider benefits and deal protections that may limit competing bids. A law firm is investigating fiduciary breaches and seeks additional consideration or disclosures on behalf of shareholders.
| Metric | Value |
|---|---|
| Price | $13.40 |
| Market Cap | $3.52B |
| P/E Ratio | 14.29 |
| EPS | $0.94 |
| Dividend Yield | 0.02% |
| 52-Week High | $19.41 |
| 52-Week Low | $5.69 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $6.16B |
| Net Income | $246.00M |
| Gross Margin | 52.81% |
5 analysts cover OGN: 0 strong buy, 0 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $11.25.